Science Stories
Extensive-stage small cell lung cancer remains one of the most aggressive and difficult-to-treat cancers, with most patients relapsing within months of initial therapy. Maintenance therapy may turn the period of stability after their first treatment into an opportunity to extend response and delay relapse.
HER2 plays an important role in cell growth and survival, but many cancers, including gastroesophageal adenocarcinoma (GEA), can overexpress this protein, leading to uncontrolled cell growth and impacting prognosis. While not everyone diagnosed with a GEA will be HER2-positive, it is helpful to test for HER2 as the presence of this protein can help inform the treatment approach.
Bispecific antibodies are showing potential in the fight against HER2-expressing cancers. This innovative approach is designed to target two specific protein receptors, providing a new and effective way to treat aggressive forms of cancer that overexpress the HER2 protein. With their ability to simultaneously target two different antigens, bispecific antibodies offer a novel approach to treating solid tumors, including the possibility for new first-line treatments.
Given the limited recognition of idiopathic hypersomnia, there is not substantial data on the burden of symptoms on those living with the disorder. Recent real-world evidence from a self-reported survey published in Nature and Science of Sleep reveals more insights around idiopathic hypersomnia symptoms and patients’ satisfaction with treatment regimens.